Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 8 December 2022

 
 
 
   

How Brussels can inject vigour into pharma sector

 
Nathalie Moll's letter to the FT
Nathalie Moll, EFPIA Director General, wrote to the Financial Times in response to their article “US subsidies for green technology ring alarm bells in EU capitals” (Report, November 21).

"Your article resonated with the European research-based pharmaceutical industry.

Competition from the US for high-tech investment is not new. In the 1990s, while half of all new treatments originated from Europe, that figure is now just one in five. In 2002, the US spent $2bn more than Europe on pharmaceutical R&D — today it is spending $25bn more. (...)"

Read more


 
 
 
   

News

 

EU-China Biopharmaceutical Innovation Roundtable
06 December 2022

Strengthening cooperation and dialogue on health and innovation Read more

Post-code lottery in European diabetes care must be addressed, says EFPIA
05 December 2022

Innovation offers the potential to improve health outcomes and quality of life for people living with diabetes. EFPIA... Read more

 
 
 
   

Podcasts

 

Why is a therapeutics waiver extension different to the vaccine waiver?
08 December 2022 - Koen Berden

While the goals of ramping up production and improving access are valid ones, not only is a waiver extension not needed,... Read more

 
 
 
   

Events

 

Enhancing patient-centric outcome measures and clinical trials with Digital Health Technologies...
12 December 2022 (Virtual event)

Last chance to register! Read more

How can we reduce premature and preventable deaths caused by cardiovascular diseases and diabetes?...
12 December 2022 (Brussels)

... Read more

IHI Call Days - Call 3
12 December 2022 (Virtual event)

Join the webinar to get information on how to apply and to meet potential partners for consortia. Read more

Launch event of the RETHINKING Alzheimer's disease White Paper
24 January 2023 (Virtual event)

Registrations are now open. Read more

 
 
 
   

‘Rare Disease Moonshot’ launched today

Scaling-up public-private partnerships to accelerate research into world’s rarest diseases

A new initiative to boost research and development into rare and paediatric diseases was launched today at the European Health Summit.

The ‘Rare Disease Moonshot’ is a commitment and collaboration between seven organisations to break down the barriers to finding new treatments and cures for the world’s rarest and severe conditions which currently have no therapeutic options, and which often affect the youngest patients.

 
 
 
 
   

What we are reading

 
BEAM Alliance’s reaction to the ‘non-paper’ issued by 14 Member states on antimicrobial market...
On 07 December 2022 (BEAM Alliance)

Check out their position paper reacting to the “non-paper” signed by 14 Member States and calling for novel stimuli... Read more

A Viable European Union Medicines Regulatory System Must be a Cornerstone for Innovation in...
On 05 December 2022 (DIA Global Forum)

In the current environment of rapidly advancing science, growing demands on data science expertise, and geopolitical... Read more

Impact of a waiver of intellectual property rights for COVID-19 therapeutics
On 05 December 2022 (IFPMA)

As WTO Member States continue to discuss an extension of a waiver of IP rights on COVID-19 therapeutics, latest evidence... Read more